Drug intelligence / Profile preview

BGS-1989

Development stage: Preclinical
Lead developer: BridGene Biosciences
Modality: Small Molecules

Overview

**BGS-1989** is a preclinical **small-molecule WDR5 inhibitor** being developed by **BridGene Biosciences** for **oncology**. WDR5 is an epigenetic scaffold protein involved in chromatin regulation and transcriptional programs that support proliferation in certain cancers, and inhibition of WDR5 is intended to disrupt WDR5-dependent oncogenic signaling. Publicly available information on BGS-1989 appears limited, but available pipeline references identify it specifically as a BridGene-discovered WDR5-targeting anticancer program in preclinical development.

Targets

WDR5 (WD repeat-containing protein 5)

Beyond the preview

Go deeper on BGS-1989.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGS-1989.

Explore the full profile